Neuroimaging in Systemic Lupus Erythematosus

Diagnostic Approach

Brain MRI with gadolinium-enhanced T1 sequences and diffusion-weighted imaging (DWI) is essential to exclude stroke, hemorrhage, cerebral venous sinus thrombosis, or inflammatory lesions in patients with systemic lupus erythematosus (SLE), as recommended by the American College of Rheumatology 1, 2
The European League Against Rheumatism suggests that CSF analysis with cell count, protein, glucose, Gram stain, culture, and viral PCR is indicated if fever, altered mental status, or meningeal signs develop in SLE patients 1, 3
Complement levels (C3, C4), anti-dsDNA antibodies, and antiphospholipid antibodies provide prognostic information for major organ involvement and should be checked, according to the British Society for Rheumatology 2, 4

Neuropsychiatric manifestations occur in 50-60% of SLE patients within the first year of diagnosis, and headache is among the most common presentations, as reported by the American College of Rheumatology 5, 6
Headache with vomiting represents a "high-risk feature" requiring comprehensive evaluation beyond standard headache assessment, as recommended by the European League Against Rheumatism 1
Normal CBC, renal function, and liver enzymes do not exclude active CNS lupus, as neurological involvement can occur independently of systemic disease activity, according to the American College of Rheumatology 5, 6

Pulse intravenous methylprednisolone combined with cyclophosphamide is the recommended regimen for severe NPSLE, with response rates of 60-75%, as suggested by the American College of Rheumatology 7
Clinical improvement should occur within days to 3 weeks with appropriate immunosuppressive therapy, according to the European League Against Rheumatism 7
Anticoagulation may be required if thrombotic mechanism is identified in SLE patients with ischemic lesions, as recommended by the British Society for Rheumatology 2

Never attribute neurological symptoms to lupus without imaging and appropriate exclusion of infection, stroke, or hemorrhage, as emphasized by the American College of Rheumatology 1, 3
Previous severe NPSLE manifestations confer at least a fivefold increased risk for subsequent neuropsychiatric events, requiring heightened vigilance, according to the European League Against Rheumatism 3
Delayed treatment initiation beyond 2 weeks is associated with severe neurological deficits, as reported by the American College of Rheumatology 7